MG 01/T 517
Alternative Names: 10,000 MG01 + 10,000 T517; 30,000 MG01 + 10,000 T517; Grasses and olea; Grasses and olea 10,000; MG01 + T517Latest Information Update: 31 Oct 2021
At a glance
- Originator Inmunotek
- Class Allergens; Allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Allergic asthma; Allergic rhinitis; Allergic rhinoconjunctivitis
Most Recent Events
- 14 Jun 2021 Phase-III clinical trials in Allergic asthma (In children, In adolescents, In adults, In the elderly) in Spain (SC) (NCT04891237)
- 14 Jun 2021 Phase-III clinical trials in Allergic rhinitis (In children, In adults, In adolescents, In the elderly) in Spain (SC) (NCT04891237)
- 14 Jun 2021 Phase-III clinical trials in Allergic rhinoconjunctivitis (In adults, In adolescents, In children, In the elderly) in Spain (SC) (NCT04891237)